Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer

Overview of attention for article published in Journal of Clinical Oncology, January 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

news: 5 news outlets
twitter: 14 X users

bluesky: 1 Bluesky user

Readers on

mendeley: 16 Mendeley

So far, Altmetric has seen 19 X posts from 14 X users, with an upper bound of 16,473 followers.

Radiotherapy combined with cetuximab improved disease-free survival in intermediate-risk head and neck cancer but not overall survival. by Machtay M, Torres-Saavedra PA (...) Le QT et 26 al. in J Clin Oncol https://t.co/WeCo2JzHok #MedX #MedResearch

RT @FundacionTTCC: Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer | Journal of Clinical Oncology https:/…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 15 additional X posts.